We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | — | — | — | $39.78M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.01 | — | — | $37.91M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.01 | — | — | $118.76M |
Consensus PT $0.25 · 1 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2023. 11. 06. | Zuanic & Associates | — | 커버리지 개시 | — → Overweight | — | Zuanic & Associates: Overweight |
| 2022. 10. 28. | BTIG | — | 커버리지 개시 | — → Buy | — | BTIG: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.01 | — | — | $78.37M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
MariMed Inc. engages in cultivation, production, and selling of branded cannabis products in the United States. The company sells cannabis flower, vapes, and concentrates under the Nature's Heritage brand; and cannabis fruit chews that delivers better sleep, pain relief, stress relief, and others under Betty's Eddies brand. It offers soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; cannabis-infused hydrating drink mix for discrete and on-the-go consumption under Vibations brand; and flower, vapes, and edibles under InHouse brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is headquartered in Norwood, Massachusetts.
Stored first · Google News · Yahoo Finance (English)
MariMed Believes Strong Brands Win Long Term Growth - The Dales Report
MariMed Believes Strong Brands Win Long Term Growth The Dales Report
Marimed president and CEO Jon Levine buys $3,000 in common stock - Investing.com
Marimed president and CEO Jon Levine buys $3,000 in common stock Investing.com
MariMed announces strategic exit from Missouri market - MSN
MariMed announces strategic exit from Missouri market MSN
MariMed Q1 2026 Earnings Call: Complete Transcript - Sahm
MariMed Q1 2026 Earnings Call: Complete Transcript Sahm
Noble Financial Maintains MARIMED INC(MRMD.US) With Buy Rating, Maintains Target Price $0.25 - Moomoo
Noble Financial Maintains MARIMED INC(MRMD.US) With Buy Rating, Maintains Target Price $0.25 Moomoo
MariMed Inc (MRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges